Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329857 | 0.81 | CHEK2 (0.36) | CHEK2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL28060420 | 0.78 | CHEK2 (0.38) | CHEK2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7836998 | 0.77 | ALDH1A1 (0.44) | CHEK2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16153149 | 0.77 | KCNA3 (0.39) | CHEK2EPHX1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL26999088 | 0.74 | ATM (0.42) | CHEK2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17930876 | 0.74 | ATM (0.42) | CHEK2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12583744 | 0.73 | CPB1 (0.55) | EPHX1NAAA | |
| SCHEMBL489210 | 0.73 | CPB1 (0.55) | EPHX1NAAA | |
| SCHEMBL30858715 | 0.73 | CPB1 (0.55) | EPHX1NAAA | |
| SCHEMBL6239705 | 0.73 | BTK (0.46) | CHEK2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | CHEK2 3130/4885EPHX1 2237/4885CHRNB2 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.